Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?

Pfizer's (PFE) stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for earnings, it missed the same for sales. Earnings of 92 cents per share rose 12% year over year due to higher gross margins and cost control. However, revenues declined 6% on an operational basis as higher sales of the Vyndaqel family, Padcev, Lorbrena, Nurtec and Comirnaty vaccine were offset by lower sales of some key products like Paxlovid, Prevnar, Xeljanz, Eliquis and Ibrance. High ...